Personalized Brain Stimulation Improves Walking Among Parkinson's Patients
By Dennis Thompson HealthDay Reporter

MONDAY, July 28, 2025 — Parkinson’s disease can dramatically affect a patient’s ability to walk, with “Parkinson’s gait” increasing their fall risk and reducing their ability to get around.
But deep brain stimulation (DBS) custom-tailored to a patient’s brain activity and gait pattern can effectively improve walking ability, a new study says.
Tweaking a patient’s brain stimulation based on analysis of factors like step length, stride speed and arm swing successfully enhanced their overall movement, researchers report in the journal npj Parkinson’s Disease.
“This work not only deepens our understanding of how DBS affects movement but also highlights the promise of personalized neuromodulation for Parkinson’s and other neurological disorders, bringing us closer to smarter more effective neuromodulation therapies,” senior researcher Dr. Doris Wang, an associate professor of neurological surgery at the University of California-San Francisco (UCSF), said in a news release.
DBS involves an implanted device that delivers electrical current directly to different areas of the brain, giving them a kick-start. It is highly effective in treating tremors, rigidity and slow movement among Parkinson’s patients, but its impact on gait has not been as reliable, researchers said in background notes.
Parkinson's disease is a progressive movement disorder that causes people to shake, become stiff or have trouble with their balance and coordination. It occurs when the brain cells that create the hormone dopamine die or become impaired.
For the new study, researchers worked with three different Parkinson’s patients to suss out a way to improve DBS’ effectiveness in treating walking problems.
During clinic visits, the patients walked in a six-meter loop while researchers adjusted their DBS settings and recorded their brain and movement activity.
Based on these readings, the researchers developed a walking performance index (WPI) that provided a comprehensive assessment of how Parkinson’s affects a person’s movement.
The team identified also brain activity patterns linked to better walking, particularly in the globus pallidus, a part of the brain associated with a loss of muscle movement in Parkinson’s patients.
“Our results confirmed that changes in DBS settings were effectively captured by the WPI, aligning with patient and clinician evaluations during each visit,” said lead researcher Hamid Fekri Azgomi, a postdoctoral scholar under Wang at UCSF.
“This validation supports that the WPI is an effective metric for assessing and targeting gait improvements in people with Parkinson’s,” Azgomi said in a news release. “Using these techniques, we were able to predict and identify personalized DBS settings that improved the WPI.”
Future research will focus on automated systems that can capture gait patterns in real-time and feed the data into DBS programming software, using the WPI to make more accurate adjustments, researchers said.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-29 00:00
Read more

- 70 Percent Say They Would Conduct At-Home Test for Suspected COVID-19
- Thresholds for Preop Serum Calcitonin Predict Lymph Node Metastasis in Thyroid Cancer
- Green Spaces Promote Better Brain Development Among Children, Study Says
- US FDA Approves GSK’s Shingrix in a Prefilled Syringe Presentation
- Health Care Expenditure Expected to Top GDP Growth 2024 to 2033
- AI Can Help Screen For Vision-Destroying Diabetic Eye Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions